Trinity Biotech plc (ADR) (NASDAQ:TRIB)

Near-term relative strength with a high enough rating here to make me confident that it hasn't topped out yet.

TECHNICALS

Growth business with great margins and a cash safety margin.

fwd P/E of 11 and a diverse diagnostics product group. Cost of revenue decresing, debt - decreased qtr over qtr by 14.7%. Improvong margins

tons of cash good management, great product range and customer spread..I diagnose acute swelling of the coffers!

The company reported positive results for drug candidate. Catalyst. Plus it has another promising drug in its pipeline that is unmatched by rivals.

I work in health care, and I believe point of care diagnostics is the wave of the future, as it has clear advantages for both the patient and the heatlth care industry, from convenience to time and cost efficiency.

It's a BS company

I picked this up totally at the wrong time (pretty much exactly 10 days too early), so I got hammered when the executive recently heavily discounted their stock to raise capital to finish paying off their 2006 purchase of the haemostasis business of French firm Biomerieux. As a result for the rest of you lucky investors out there, however, the stock is now sitting pretty at around 20% down from what I already considered a heck of a deal. I really wish I had the opportunity to buy into this company for the first time at this price and ride it from here.

Also, if you want more convincing, O'Caoimh, the executive chairman, just picked up 250,000 shares to supplement the 100,000 he bought on March 20. Not that insider trading necessarily means anything, but it's always nice to see executives having just bought over $1 milliion in their own company. http://www.forbes.com/markets/feeds/afx/2008/04/15/afx4890516.html

I see serious gains over the next year or two, maybe not all the way back up to to around 20, but at least to 10 (+ 300%). Here's hoping I'm right.

Undervalued.

The opportunities in this field are phenominal as the development of the laser knife has cracked the industry wide open. With so many advancements in technology advancing the causes in medical diagnostics as long as they don't invest in the Edsel they should continue to grow and provide a return on investment.

Experiment time... I will pick whatever stocks that are on the cold 5 star list on the last trading day of each month. There is no research involved other what is on the cold 5 star list at the end of each month. Each pick will be for one year. Lets see where this goes...

extremely undervalued.

45% growth rate with an unlimited potential...if there is ever an unknown pandemic(praying that this will not be so), TRIB will be a scorcher. BTW: I have owned this stock(bought as a penny stock) for about 8 years and I am waiting for the big bounce which I anticipate in the next year or so. I refuse to sell this one!

Best fundamentals of all the stock I bought before the Bubble burst...only one still invested. Catch it if it falls blow $9 then hold for retirement(I hope).

mostly a solid company that had a really bad day. also any stock with a price/book less than one is basically guaranteed.

There is good growth potential for rapid diagnostics, especially in developing countries where AIDS continues to be a problem. TRIB is well positioned to benefit from this growth. TRIB is capturing new market share in NA and EU markets as well.

TRIB has a successful record of growth both organic and via acquisition.

TRIB has also shown consistent revenue and EBITDA growth, indicating that management has been successful in keeping costs in line with growth.

Aids product coming to market

Home AIDS test kit will be huge